At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 6 enrolled
Drug / intervention
radioactive drug (tracer) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
PET/CT Quantitative Assessment of Myocardial Blood Flow Changes in Oncologic Patients Receiving Checkpoint Inhibitor Therapy
In Brief
A Phase 2 clinical trial evaluating PET/CT and radioactive drug (tracer) for Cancer. Completed, enrolled 6 participants across 1 site.
Detailed Summary
Researchers are trying to determine the side effects on the heart from immune checkpoint inhibitor (ICI) treatment in patients with cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
Enrollment StartAug 2020
First PostedSep 2020
Primary CompletionMay 2022
TodayJul 2026
First PostedSep 4, 2020
Enrollment StartAug 14, 2020
Primary CompletionMay 19, 2022
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 5.8 years ago
Interventions
PET/CTother
Positron emission tomography-computed tomography is an image test that helps show detail about how tissues and organs are functioning.
radioactive drug (tracer)drug
A radioactive drug (tracer) is used in the PET scan.